menu

Optimizing Outcomes & Improving Adherence: Use of Long-Acting Injectables in Early Schizophrenia

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing Outcomes & Improving Adherence: Use of Long-Acting Injectables in Early Schizophrenia

close
0.50 credits
30 minutes
Optimizing Outcomes & Improving Adherence: Use of Long-Acting Injectables in Early Schizophrenia
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    The prevention of a subsequent psychotic episode and resulting hospitalization in people with early phase schizophrenia is a key public health problem with substantial consequences. Previous research has shown that second episodes of psychosis in the same individual respond less well to the same treatment. Therefore, the prevention of psychotic episodes with proper medications and therapies is crucial for their prospects toward longer-term recovery. Unfortunately, adherence to antipsychotic medication is low and long-acting injectable antipsychotic medications are underutilized. New research is emerging that demonstrates how long-acting injectables, which have been traditionally reserved for patients at later periods of their disease, can be utilized for first or early episodes of schizophrenia to achieve optimal outcomes.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:
    John M. Kane, MD has disclosed the following relevant financial relationships:
    Consultant for: Acadia, Alkermes, Allergan, Eli Lilly, Forum, Genentech, H. Lundbeck, Sumimoto Dainippon
    Grants from: Otsuka, H. Lundbeck and Janssen  
    Shareholder: Vanguard Research Group and LB Pharmaceuticals

    John J. Russell, MD (host) has disclosed the following relevant financial relationships: 
    Consultant and Advisory Board Member:  GlaxoSmithKline
    Speaker and Advisory Board Member: Sanofi

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:
    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.

  • Learning Objectives

    • Recognize the need for a therapeutic alliance and a patient-centered approach to optimize outcomes in schizophrenia;
    • Assess the benefits and the barriers for the early initiation of LAIs in the treatment of schizophrenia;
    • Evaluate recent studies and examine ramifications for the early initiation or recent onset use of LAIs in schizophrenia.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Method of Participation and Receipt of Credit
    In order to receive credit, participants should watch the entire video. Upon completion of the video, please continue to the post-test and evaluation. A passing score of 70% on the post-test is required to receive credit.  There is no fee for this activity.  

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This program is supported by an educational grant from Alkermes, Inc. and Otsuka America Pharmaceutical, Inc. and alliance partner, Lundbeck.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The prevention of a subsequent psychotic episode and resulting hospitalization in people with early phase schizophrenia is a key public health problem with substantial consequences. Previous research has shown that second episodes of psychosis in the same individual respond less well to the same treatment. Therefore, the prevention of psychotic episodes with proper medications and therapies is crucial for their prospects toward longer-term recovery. Unfortunately, adherence to antipsychotic medication is low and long-acting injectable antipsychotic medications are underutilized. New research is emerging that demonstrates how long-acting injectables, which have been traditionally reserved for patients at later periods of their disease, can be utilized for first or early episodes of schizophrenia to achieve optimal outcomes.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:
    John M. Kane, MD has disclosed the following relevant financial relationships:
    Consultant for: Acadia, Alkermes, Allergan, Eli Lilly, Forum, Genentech, H. Lundbeck, Sumimoto Dainippon
    Grants from: Otsuka, H. Lundbeck and Janssen  
    Shareholder: Vanguard Research Group and LB Pharmaceuticals

    John J. Russell, MD (host) has disclosed the following relevant financial relationships: 
    Consultant and Advisory Board Member:  GlaxoSmithKline
    Speaker and Advisory Board Member: Sanofi

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:
    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.

  • Learning Objectives

    • Recognize the need for a therapeutic alliance and a patient-centered approach to optimize outcomes in schizophrenia;
    • Assess the benefits and the barriers for the early initiation of LAIs in the treatment of schizophrenia;
    • Evaluate recent studies and examine ramifications for the early initiation or recent onset use of LAIs in schizophrenia.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Method of Participation and Receipt of Credit
    In order to receive credit, participants should watch the entire video. Upon completion of the video, please continue to the post-test and evaluation. A passing score of 70% on the post-test is required to receive credit.  There is no fee for this activity.  

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This program is supported by an educational grant from Alkermes, Inc. and Otsuka America Pharmaceutical, Inc. and alliance partner, Lundbeck.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/29/20